In this issue:
Androgen deprivation therapy and depression
Factors influencing prostate cancer treatment decisions
Circulating tumour DNA alterations in patients with mCRPC
Diet quality and Gleason grade progression during active surveillance
PROSPER: enzalutamide vs placebo for nmCRPC
The role of REST in neuroendocrine differentiation of CRPC
Time to treatment and outcome of high/very-high-risk prostate cancer
Trajectory of patients who die from metastatic prostate cancer
Guidelines on hypofractionated radiation therapy for localised prostate cancer
Local treatment in patients aged ≥75 years with locally advanced prostate cancer
Please login below to download this issue (PDF)